Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CNA3103
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Carina Biotech Doses First Patient in Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy
Details : CNA3103 is a LGR5-targeted CAR-T cell therapy candidate which is being evaluated in phase 1/2 clinical trials for the treatment of adult patients with metastatic colorectal cancer (mCRC).
Product Name : CNA3103
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 18, 2023
Lead Product(s) : CNA3103
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CNA3103
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CNA3103 is a LGR5 targeted CAR-T cells have potential to be developed as a novel immunotherapy to kill ovarian cancer cells and to reduce ovarian cancer tumor.
Product Name : CNA3103
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 02, 2023
Lead Product(s) : CNA3103
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CNA3103
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CNA3103 CAR-T cell targets LGR5, a cancer stem cell marker that is highly expressed on advanced colorectal cancer and some other cancers. CNA3103 have shown promising results with complete tumor regression and no tumor recurrence following a single admin...
Product Name : CNA3103
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 24, 2023
Lead Product(s) : CNA3103
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CNA3103
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Carina’s CAR-T cell therapy candidate, CNA3103, is targeted at LGR5, a cancer stem cell marker that is highly expressed on advanced colorectal cancer and some other cancers.
Product Name : CNA3103
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 12, 2022
Lead Product(s) : CNA3103
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Tenmile
Deal Size : $7.5 million
Deal Type : Financing
Carina Biotech Raises $7.5 Million at First Close with Tenmile as The Cornerstone Investor
Details : The capital raise enables Carina to complete its Investigational New Drug (IND) enabling studies and initiate a CAR-T clinical trial of LGR5 CAR-T cell for patients with advanced colorectal (bowel) cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 18, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Tenmile
Deal Size : $7.5 million
Deal Type : Financing